SAfit2 manufacturers
- SAFit2
-
- $84.00 / 1mg
-
2025-07-22
- CAS:1643125-33-0
- Min. Order:
- Purity: 99.96%
- Supply Ability: 10g
|
| Product Name: | SAfit2 | | Synonyms: | SAfit2;2-Piperidinecarboxylic acid, 1-[(2S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-(4-morpholinyl)ethoxy]phenyl]propyl ester, (2S)-;(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl (S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate;(1R)-3-(3,4-dimethoxyphenyl)-1-{3-[2-(morpholin-4-yl)ethoxy]phenyl}propyl (2S)-1-[(2S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;SAFit2, 10 mM in DMSO | | CAS: | 1643125-33-0 | | MF: | C46H62N2O10 | | MW: | 802.99 | | EINECS: | | | Product Categories: | | | Mol File: | 1643125-33-0.mol |  |
| | SAfit2 Chemical Properties |
| Boiling point | 877.0±65.0 °C(Predicted) | | density | 1.168±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 50 mg/ml; DMSO: 50 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 10 mg/ml | | form | A crystalline solid | | pka | 6.43±0.10(Predicted) | | color | Off-white to pink | | InChIKey | ZDBWLRLGUBSLPG-FDHYQTMZSA-N | | SMILES | N1(C([C@@H](C2CCCCC2)C2=CC(OC)=C(OC)C(OC)=C2)=O)CCCC[C@H]1C(O[C@@H](C1=CC=CC(OCCN2CCOCC2)=C1)CCC1=CC=C(OC)C(OC)=C1)=O |
| | SAfit2 Usage And Synthesis |
| Description | SAfit2 is a potent inhibitor of FK506-binding protein 51 (FKBP51; Ki = 6 nM). It is highly selective for FKBP51 over FKBP52 (Ki = >50,000 nM) and has increased brain permeability in comparison to SAfit1. SAfit2 (20 mg/kg) enhances HPA axis suppression in mice by decreasing plasma corticosterone levels to a greater extent than in control mice following dexamethasone administration. It also does not increase plasma corticosterone levels as high as in control mice following subsequent administration of corticotropin-releasing factor (CRF; ). It decreases the time spent immobile in the forced swim test and increases the time spent in the open arms of the elevated plus maze, indicating antidepressant-like and anxiolytic-like activity, respectfully. | | Uses | SAFit2 is a highly selective inhibitor of FKBP51. The selective inhibition of FKBP51, using SAFit1(S139583) & SAFit2 , has shown to enhances neurite elongation in neuronal cultures and improves neuroendocrine feedback and stress-coping behavior in mice. | | in vivo | It is found that 30 days of SAFit2 administration leads to a reduction in body weight under both control and high-fat diet (HFD) conditions. SAFit2 significantly increases phosphorylated AKT2 and AS160 in EDL muscle and likewise increases expression of GLUT4 at the membrane in soleus muscle[2]. When SAFit2 is applied 1 h before testing, no alterations in anxiety-related behavior are observed. However, SAFit2 treatment induces an anxiolytic phenotype in mice injected 16 h prior testing, which is reflected in a significantly increased open arm time in the elevated plus maze (EPM) (z=-2.183, p<0.05).? SAFit2 treatment leads to a significantly reduced latency to enter the lit compartment (z=-2 to 265, p<0.05), as well as a significantly increased distance traveled (t(20)=-2.371, p<0.05) in the lit compartment[3]. |
| | SAfit2 Preparation Products And Raw materials |
|